EUVIMEDEUVIMED entdecken
Crossref

Comparative Prognostic Performance of Liver Function Scores in Unresectable Hepatocellular Carcinoma Treated with First-Line Sorafenib

Safa Can Efil, Mehmet Akif Parlar, Şeyma Erdoğan, Burak Merhan, Efnan Algın, Şebnem Yücel, Burak Bilgin, Muhammed Bülent Akıncı, Bülent Yalçın, Mehmet Ali Şendur

Uludağ Üniversitesi Tıp Fakültesi Dergisi · 10.11.2026 · 52

DOI: 10.32708/uutfd.2038665 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Uludağ Üniversitesi Tıp Fakültesi Dergisi, online erschienen am 10.11.2026. Verfasst von Safa Can Efil und 9 weiteren Autor:innen. Die Arbeit nennt 24 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study compared the prognostic performance of four liver function scores (the Child–Pugh score, Model for End-Stage Liver Disease [MELD], Model for End-Stage Liver Disease-Sodium [MELD-Na], and MELD 3.0) in patients with unresectable hepatocellular carcinoma receiving first-line sorafenib. A total of 120 patients treated between June 2019 and April 2025 were included in this retrospective, single-center cohort. Overall survival (OS) was the primary outcome. The discriminatory performance of the four scores was assessed at 3, 6, and 12 months using time-dependent receiver operating characteristic analysis, and their associations with OS were evaluated using Cox regression. During follow-up, 107 patients (89.2%) died, and median OS was 5.62 months. MELD 3.0 showed the highest discrimination at 3, 6, and 12 months, with area under the curve values of 0.769, 0.790, and 0.710, respectively. At 6 months, MELD 3.0 showed significantly better discrimination than MELD and MELD-Na after adjustment for multiple comparisons, whereas no significant difference was observed between MELD 3.0 and the Child–Pugh score. In multivariable analysis, MELD 3.0 and Eastern Cooperative Oncology Group performance status remained independently associated with OS. In an exploratory analysis, median OS was 10.78 months in patients with MELD 3.0 <10 and 4.07 months in those with MELD 3.0 ≥10. MELD 3.0 may provide an objective measure of hepatic reserve for risk stratification in patients with unresectable hepatocellular carcinoma, although its performance was not superior to the Child–Pugh score.

Zitieren

APA

Efil, S. C., Parlar, M. A., Erdoğan, Ş., Merhan, B., Algın, E., Yücel, Ş., Bilgin, B., Akıncı, M. B., Yalçın, B., & Şendur, M. A. (2026). Comparative Prognostic Performance of Liver Function Scores in Unresectable Hepatocellular Carcinoma Treated with First-Line Sorafenib. Uludağ Üniversitesi Tıp Fakültesi Dergisi, 52. https://doi.org/10.32708/uutfd.2038665

Vancouver

Efil SC, Parlar MA, Erdoğan Ş, Merhan B, Algın E, Yücel Ş, et al. Comparative Prognostic Performance of Liver Function Scores in Unresectable Hepatocellular Carcinoma Treated with First-Line Sorafenib. Uludağ Üniversitesi Tıp Fakültesi Dergisi. 2026;52. doi:10.32708/uutfd.2038665

BibTeX
@article{Efil2026,
  author = {Efil, Safa Can and Parlar, Mehmet Akif and Erdoğan, Şeyma and Merhan, Burak and Algın, Efnan and Yücel, Şebnem and Bilgin, Burak and Akıncı, Muhammed Bülent and Yalçın, Bülent and Şendur, Mehmet Ali},
  title = {Comparative Prognostic Performance of Liver Function Scores in Unresectable Hepatocellular Carcinoma Treated with First-Line Sorafenib},
  journal = {Uludağ Üniversitesi Tıp Fakültesi Dergisi},
  year = {2026},
  volume = {52},
  doi = {10.32708/uutfd.2038665}
}
Kostenlos starten →